MARKET

WINT

WINT

Windtree Therapeutics Inc
NASDAQ
0.8522
+0.0033
+0.39%
After Hours: 0.8500 -0.0022 -0.26% 19:49 05/09 EDT
OPEN
0.8350
PREV CLOSE
0.8489
HIGH
0.8600
LOW
0.8147
VOLUME
137.81K
TURNOVER
--
52 WEEK HIGH
737.44
52 WEEK LOW
0.8147
MARKET CAP
3.11M
P/E (TTM)
-0.0082
1D
5D
1M
3M
1Y
5Y
1D
Healthcare stocks that could be poised for a rebound
Seeking Alpha · 1d ago
Windtree receives advice from IP, FDA on exclusivity strategy for istaroxime
TipRanks · 5d ago
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
Barchart · 5d ago
Weekly Report: what happened at WINT last week (0428-0502)?
Weekly Report · 6d ago
Windtree Therapeutics enters Assignment, Conditional Assumption Agreement
TipRanks · 05/01 13:16
Windtree Therapeutics Raises $2.5M in Private Placement
TipRanks · 05/01 12:55
Windtree Therapeutics Secures Rights To Acquire 436-Unit Multifamily Property In Houston
Benzinga · 05/01 12:34
Weekly Report: what happened at WINT last week (0421-0425)?
Weekly Report · 04/28 11:35
More
About WINT
More
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Its lead product candidate, istaroxime, is a dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure (AHF) and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. The Company also has a licensing business model with partnership out-licenses in place.
Recently
Symbol
Price
%Change

Webull offers Windtree Therapeutics Inc stock information, including NASDAQ: WINT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, WINT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading WINT stock methods without spending real money on the virtual paper trading platform.